In a report released today, Paul Choi from Goldman Sachs maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report), with a price target of $32.00. The company’s shares opened today at $16.84.
According to TipRanks, Choi is a 4-star analyst with an average return of 12.6% and a 55.56% success rate. Choi covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, FibroGen, and Ascendis Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kiniksa Pharmaceuticals with a $32.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $17.20 and a one-year low of $9.63. Currently, Kiniksa Pharmaceuticals has an average volume of 432.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
Read More on KNSA:
- Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
- KNSA Upcoming Earnings Report: What to Expect?
- Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
- Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
